Edition:
United Kingdom

BioXcel Therapeutics Inc (BTAI.OQ)

BTAI.OQ on NASDAQ Stock Exchange Capital Market

6.39USD
18 Oct 2018
Change (% chg)

$-0.19 (-2.89%)
Prev Close
$6.58
Open
$6.55
Day's High
$6.55
Day's Low
$6.25
Volume
2,473
Avg. Vol
9,350
52-wk High
$14.28
52-wk Low
$5.80

Latest Key Developments (Source: Significant Developments)

Bioxcel Therapeutics Expands Immuno-Oncology Partnership With Nektar
Monday, 24 Sep 2018 

Sept 24 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS EXPANDS IMMUNO-ONCOLOGY PARTNERSHIP WITH NEKTAR INTO CLINICAL DEVELOPMENT IN PANCREATIC CANCER.BIOXCEL THERAPEUTICS INC - CO AND NEKTAR ARE EXPANDING THEIR ONGOING RESEARCH COLLABORATION INTO A NEW CLINICAL PARTNERSHIP.BIOXCEL THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, CO WILL BE RESPONSIBLE FOR INITIATING AND MANAGING CLINICAL PROGRAM.  Full Article

Bioxcel Therapeutics Reports Q2 Net Loss Per Share $0.1
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.CLINICAL PROGRAMS IN NEUROSCIENCE (BXCL501) AND IMMUNO-ONCOLOGY (BXCL701) ON TRACK.QTRLY NET LOSS PER SHARE $0.1.  Full Article

Bioxcel Therapeutics Reports Positive Results From Phase 1B Trial Of Intravenously-Dosed Dexmedetomidine Supporting Bxcl501 Development
Wednesday, 27 Jun 2018 

June 27 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS POSITIVE RESULTS FROM PHASE 1B TRIAL OF INTRAVENOUSLY-DOSED DEXMEDETOMIDINE SUPPORTING BXCL501 DEVELOPMENT.BIOXCEL THERAPEUTICS INC - OPTIMAL EXPOSURE LEVELS FOR DEVELOPING BXCL501 SUBLINGUAL THIN FILM IDENTIFIED.BIOXCEL - RESULTS SUPPORT CLINICAL EVALUATION OF DEXMEDETOMIDINE IN ACUTE TREATMENT OF AGITATION RESULTING FROM NEUROPSYCHIATRIC DISORDERS & DEMENTIA.BIOXCEL THERAPEUTICS INC - IV FORMULATION OF DEX WAS WELL TOLERATED.  Full Article

Bioxcel Therapeutics Reports Q1 Loss Per Share $0.37
Monday, 14 May 2018 

May 14 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.BIOXCEL THERAPEUTICS INC QTRLY LOSS PER SHARE $0.37.  Full Article

Bioxcel Therapeutics Shares Open Slightly Above IPO Price
Thursday, 8 Mar 2018 

March 8 (Reuters) - :BIOXCEL THERAPEUTICS INC SHARES OPEN AT $11.02 IN DEBUT ON NASDAQ VERSUS IPO PRICE OF $11.00/SHARE.  Full Article